Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering gene editing technologies and developing gene editing therapies, the company has multiple product candidates in the pipeline, including treatment for metabolic, cardiovascular, viral hepatitis, ocular and rare diseases.
Location: China
Employees: 51-200
Total raised: $92M
Founded date: 2021
Investors 2
| Date | Name | Website |
| 25.10.2023 | OrbiMed | orbimed.co... |
| 12.01.2024 | Qiming Ven... | qimingvc.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.09.2025 | Series B | $60M | OrbiMed |
| 01.09.2023 | Series A | $32M | - |
Mentions in press and media 10
| Date | Title | Description |
| 08.09.2025 | Epigenic Therapeutics Announces Completion of $60 Million Series B Financing to Accelerate Clinical Development of Epigenetic Medicines | SHANGHAI, Sept. 8, 2025 /PRNewswire/ -- Epigenic Therapeutics ("Epigenic"), a clinical-stage innovative drug development company, today announced the completion of a $60 million Series B round of financing led by Lapam Capital, wi... |
| 08.09.2025 | Epigenic Therapeutics Closes $60M Series B Financing | Epigenic Therapeutics, a Shanghai, China-based clinical-stage drug development company, raised $60M in Series B funding. The round was led by Lapam Capital, with participation from existing investors Qiming Venture Partners and OrbiMed, and... |
| 20.11.2024 | Epigenic Therapeutics to Enter Clinical Development of EPI-003: A First-in-Class Epigenetic Inactivator for the Treatment of Chronic Hepatitis B | SHANGHAI, Nov. 20, 2024 /PRNewswire/ -- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, today announced that it has received approval of clinical trial application (CTA... |
| 01.09.2023 | China-based Epigenic Therapeutics raises USD 32 million in Series A | Shanghai, China-based leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, Epigenic Therapeutics raised USD 32 million in Series A. The com... |
| 31.08.2023 | Deals in brief: Markato backed to transform B2B wholesale in Asia, three major deals in China, and more | Amidst the funding winter, Indian startup Zepto has defied trends by becoming the country’s first unicorn this year after completing a USD 200 million Series E funding round. Commerce, whether retail or online, is a highly saturated industr... |
| 30.08.2023 | Deals in brief: MFast raises Series A funds to expand nationwide, multiple China and SEA deals, and more | MFast completes Series A round to expand financial services in Vietnam The Vietnam-based financial services platform has concluded its Series A funding round, raising around USD 6 million. The round was led by Wavemaker Partners and saw par... |
| 30.08.2023 | Epigenic Therapeutics Raises $32M in Series A Funding | Epigenic Therapeutics, a Shanghai, China-based biotechnology company dedicated to developing gene modulation therapy to treat prevalent diseases, raised $32M in Series A funding. The round was co-led by Qiming Venture Partners and OrbiMed, ... |
| 30.08.2023 | Epigenic Therapeutics Announces $32 Million in Series A Funding to Bring Breakthrough Epigenome Medicine to Clinical Development | SHANGHAI, Aug. 30, 2023 /PRNewswire/ -- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, today announced that ... |
| 08.08.2022 | Epigenic Therapeutics Raises $20M in Series Angel and Pre-A Funding | Epigenic Therapeutics, a Shanghai, China-based biotechnology company, raised $20M in Series Angel and Pre-A funding. Backers included Morningside Venture Capital, Kingray Capital, Trinity Innovation Fund, TigerYeah Capital and FountainBridg... |
| - | Epigenic Therapeutics | “Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene modulation therapy utilizing regulation of epigenetic genome for a variety of diseases.” |